SARS-CoV-2 Proteins and Their Target Proteins

Featured Interaction Proteins

Coronavirus Proteins

Recently, South Africa has detected a new mutant of the Sars-CoV-2-B.1.1.529. The World Health Organization (WHO) included B.1.1.529 on the Variant of Concern (VOC), named Omicron.

B.1.1.529 contains at least 50 mutations, 30 of which are on the spike protein (S protein). Not surprisingly, spike protein has become the research and development target of most vaccines. Some of the mutations are known to affect infectivity and immune escape, while others are newly identified. It is currently unknown what will happen when these mutations combine and their effects on the Sars-CoV-2 vaccine.

Creative BioMart is still committed to overcoming the challenges posed by the COVID-19 pandemic. We have just added a new panel of mutant RBD/spike and nucleocapsid proteins. In addition to the Omicron variant, Creative BioMart also provides other COVID variants (Alpha, Beta, Gamma, Delta, Eta, Iota, Kappa, and Lambda). We will continue to update our catalog to include new mutant proteins. Please contact us for more information.

According to the new statistics from the WHO, there are 147 vaccine projects in various stages of development worldwide for the COVID19, of which 18 have entered clinical trials.

Coronavirus uses its spike glycoprotein (S), a main target for neutralization antibody, to bind to its receptor, and mediate membrane fusion and virus entry. Its receptor binding domain (RBD) has a high affinity with the ACE2 receptor protein on the surface of human cells. The S protein is an ideal entry point for vaccine design. The neutralizing antibody binds to the viral S protein RBD to competitively block the virus binding to the ACE2 protein and infect cells, achieving the effect of immune prevention and even treatment.

We can now offer mutant spike RBD proteins, which are thermally stable and can produce antibodies with neutralizing activity. We will continue to work together with the worldwide scientists to find the path forward for today’s challenges, and to support tomorrow’s breakthroughs.

NRP1: Another Target for SARS-CoV-2?

The global spread of COVID19 continues unabated. Compared with the SARS virus 17 years ago, SARS-CoV-2 is more contagious, and the scope and severity of the new coronavirus far exceed the SARS epidemic in 2003. Considering there are no significant differences in the binding affinity constants of ACE2 and RBD, it is not possible to fully explain the reason why the infection and transmission capacity of the new crown has increased compared with SARS. Therefore, binding of SARS-CoV-2’s Spike protein to host ACE2 triggers viral entry, but other proteins may participate.

New research found that neuropilin-1 (NRP1), known to bind furin-cleaved substrates, significantly potentiates SARS-CoV-2 infectivity. Pathological analysis of human COVID-19 autopsies revealed SARS-CoV-2 infected cells including olfactory neuronal cells facing the nasal cavity positive for NRP1. X-ray crystallography, antibody blocking, and other biochemical approaches show that the S1 CendR motif directly bound NRP1. Blocking this interaction using RNAi or selective inhibitors reduced SARS-CoV-2 entry and infectivity in cell culture. Thus NRP1 may potentially provide a therapeutic target for COVID-19.

Creative BioMart provides high-quality labeled NRP1 proteins. For more protein product information or custom protein expression service, please feel free to contact us. Together we will win the fight!

Customized expression service of mutant SARS-CoV-2 protein

A terrible mutant strain of the new coronavirus was discovered in the United Kingdom. The binding affinity of the S protein to the human ACE2 receptor has increased by 1,000 times, and the transmission speed is as high as 70% compared with the previous strain; it soon became the main strain in the London area. This new strain has 23 special mutations and is named subtype B.1.1.7.

Estimates suggest that circulating SARS-CoV-2 lineages accumulate nucleotide mutations at a rate of about 1-2 mutations per month. The B.1.1.7 lineage carries a larger than the usual number of virus genetic changes. The accrual of 14 lineage-specific amino acid replacements prior to its detection is, to date, unprecedented in the global virus genomic data for the COVID-19 pandemic.

The epidemiological significance of the replication characteristics, transmission characteristics, and impact on vaccination of this B.1.1.7 strain is still unclear. In addition to the obvious increase in the spread of the new strain, there are other dangers waiting to be verified.

Virus mutation is a natural phenomenon that has always occurred. The new coronavirus mutant strain will cause the speed of transmission to increase, which may be due to the increased binding affinity of the mutant virus strain S protein to the human ACE2 receptor. The mutation helps the virus escape the host's immune response, and also leads to antigen drift, making the COVID-19 as difficult to prevent as flu.

Creative BioMart provides customized expression services, especially for mutant SARS-CoV-2 protein. Single mutant, multiple mutants, deletion, or insert mutant can be customized according to customer requirements. We currently have a batch of RBD mutant products (Find product information on RBD Mutant Proteins). If the mutant you need is not on the product list, you can contact us for inquiries or customize it as required.